Developing an RNA vaccine to enhance the immune response against HIV
Engineering the Immune Response of a Self-replicating and Adjuvanting RNA HIV-1Vaccine
['FUNDING_OTHER'] · HDT BIO CORPORATION · NIH-11084572
This study is testing a new mRNA vaccine that aims to help your immune system fight HIV-1 by encouraging it to produce strong antibodies, using a special delivery method to make it work better.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | HDT BIO CORPORATION (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-11084572 on ClinicalTrials.gov |
What this research studies
This research focuses on creating a messenger RNA (mRNA) vaccine designed to stimulate the immune system to produce broadly neutralizing antibodies against HIV-1. The vaccine utilizes a novel delivery system involving lipid inorganic nanoparticles to enhance its effectiveness. By optimizing the formulation and administration of this vaccine, the researchers aim to improve B cell differentiation and antibody production, which are crucial for effective immunity. The project builds on previous successes with mRNA vaccines and aims to advance the development of a viable HIV vaccine.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals at high risk for HIV infection, particularly those who are unvaccinated and between the ages of 0-11.
Not a fit: Patients who are already HIV-positive or those with severe immunocompromising conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective vaccine against HIV, potentially reducing the incidence of HIV infections.
How similar studies have performed: Previous research with mRNA vaccines has shown promising results, indicating that this approach has the potential for success in developing an effective HIV vaccine.
Where this research is happening
SEATTLE, UNITED STATES
- HDT BIO CORPORATION — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KHANDHAR, AMIT PRAFUL — HDT BIO CORPORATION
- Study coordinator: KHANDHAR, AMIT PRAFUL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus